Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kite And Juno Threatened By Cellectis' Off-The-Shelf CAR-T Success

This article was originally published in Start Up

Executive Summary

An unexpected breakthrough announced by Cellectis for its experimental off-the-shelf CAR-T therapy has raised the possibility that much-hyped therapies using a patient's own cells, under development at Kite Pharma and Juno Therapeutics may become commercially obsolete before they even reach the market.

Advertisement

Related Content

Synthetic Biology And The Computerization Of Drug Development
Juno, Kite Stand By Their Products As Novartis's Shift Renews CAR-T Concerns

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC092688

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel